Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide interaction study with morphine and edoxaban in prostate cancer
NL-OMON53933Phase 4Recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of enzalutamide, morphine and edoxaban in prostate cancer (PCa) (4 arms), sponsored by Radboud University Medical Center. Primary endpoints: Change in edoxaban exposure, Change in M4 exposure and 2 more. Started Feb 2023; status: recruiting.
02
Drugs
enzalutamidemorphineedoxaban
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON53933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53933.